GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Morphic Holding Inc (STU:31Y) » Definitions » Institutional Ownership

Morphic Holding (STU:31Y) Institutional Ownership : 56.40% (As of May. 20, 2024)


View and export this data going back to 2019. Start your Free Trial

What is Morphic Holding Institutional Ownership?

Institutional ownership is the percentage of shares that are owned by institutions out of the total shares outstanding. As of today, Morphic Holding's institutional ownership is 56.40%.

Insider Ownership is the percentage of shares that are owned by company insiders relative to the total shares outstanding. As of today, Morphic Holding's Insider Ownership is 0.00%.

Float Percentage Of Total Shares Outstanding is the percentage of float shares relative to the total shares outstanding. As of today, Morphic Holding's Float Percentage Of Total Shares Outstanding is 69.19%.


Morphic Holding Institutional Ownership Historical Data

The historical data trend for Morphic Holding's Institutional Ownership can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Morphic Holding Institutional Ownership Chart

Morphic Holding Historical Data

The historical data trend for Morphic Holding can be seen below:

2023-06-30 2023-07-31 2023-08-31 2023-09-30 2023-10-31 2023-11-30 2023-12-31 2024-01-31 2024-02-29 2024-03-31
Institutional Ownership 56.43 56.28 56.22 52.49 52.81 53.64 55.81 56.50 56.30 56.40

Morphic Holding Institutional Ownership Calculation

The percentage of shares that are owned by institutions out of the total shares outstanding.


Morphic Holding (STU:31Y) Business Description

Traded in Other Exchanges
Address
35 Gatehouse Drive, A2, Waltham, MA, USA, 02451
Morphic Holding Inc is a biopharmaceutical company applying its insights into integrins to discover and develop a pipeline of oral small-molecule integrin therapeutics. Integrins are a target class with multiple approved injectable blockbuster drugs for the treatment of serious chronic diseases, including autoimmune, cardiovascular, and metabolic diseases, fibrosis, and cancer.

Morphic Holding (STU:31Y) Headlines

No Headlines